vTv Therapeutics (VTVT)
Develops oral small molecules for diabetes, centered on cadisegliatin alongside insulin.
Something off on this page? Send us feedback.
Develops oral small-molecule treatments for diabetes and other chronic diseases, centered on cadisegliatin, an adjunct-to-insulin candidate for type 1 diabetes. The clinical-stage business has no marketed drug sales and derives revenue primarily from collaboration and license arrangements.
Develops oral small-molecule treatments for diabetes and other chronic diseases, with cadisegliatin as its central program. The liver-selective glucokinase activator is being studied alongside insulin for type 1 diabetes in the U.S. Phase 3 CATT1 trial.
The business is concentrated around clinical development rather than marketed medicines: it has not generated drug-sales revenue, and collaboration and license arrangements have supplied revenue. HPP737 is licensed worldwide to Newsoara Biopharma for development and commercialization.
Progress depends on CATT1 enrollment, clinical outcomes, regulatory review, and potential approval. FDA previously placed the program on clinical hold before lifting it after the company's response.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 6, 2026 | H.C. Wainwright | Target | $47 | $42 | |
| Jun 30, 2026 | Rodman & Renshaw | Initiate | Buy | ||
| Jan 27, 2026 | BTIG | Reiterate | Buy | $49 | |
| Jan 22, 2026 | Roth Capital | Target | $58 | ||
| Dec 19, 2025 | H.C. Wainwright | Target | $47 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $86.6M · Total debt $0 · Total assets $87.6M · Shareholders' equity $78.6M
- Revenue
- $0
- Operating income
- −$13.9M
- Net income
- −$13.1M
No dividends on record.
| Institutions44 holders · as of Jun 30, 2026 | 40.65% | 1.61M shares | |
| Insiders4 holders · as of Feb 18, 2026 | 28.88% | 1.14M shares | |
| Strategic holders1 holder · as of Dec 6, 2024 | 5.23% | 206.8K shares | |
| Otherremainder | 25.24% | 998.0K shares |
3.95M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (3.95M in the company's Sep 3, 2026 report, 2.62M elsewhere); stakes use the report.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Srinivas Akkaraju1Insiderdirector | 10.22% | 403,942 A | 13Dfiled Dec 9, 2025 ↗ |
Paul J. SekhriInsiderdirector, officer: Pres, CEO and Exec Chairperson | 9.92% | 392,212 A | Form 4filed Feb 18, 2026 ↗ |
Invus Public Equities, L.P.Insider | 8.75% | 345,926 | 13Gfiled Nov 12, 2025 ↗ |
Samsara Biocapital, LLCInstitution | 7.55% | 298,496 A | 13Fas of Jun 30, 2026 |
Millennium Management LLCInstitution | 6.83% | 269,874 A | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
- Srinivas Akkaraju's transaction reports restate only vehicles that traded; the 2025 ownership statement (403.9K) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- MiniMed Group
Integrated automated insulin delivery for T1D glycemic management
- Insulet
Tubeless automated insulin delivery for T1D control and low protection
- Tandem Diabetes Care
Predictive automated insulin delivery for T1D low and high control
- Beta Bionics
Autonomous insulin dosing for T1D glycemic management
- Vertex Pharmaceuticals
Investigational islet-cell therapy for severe T1D hypoglycemia
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| vTv Therapeutics | $33.61 | +5.20% | $87.4M | — | — | 2.4 | — |
| MiniMed Group | $24.00 | +1.14% | $6.67B | — | 41.2 | 2.1 | — |
| Insulet | $149.45 | +0.90% | $10.26B | 27.7 | 21.5 | 3.4 | +23.5% |
| Tandem Diabetes Care | $20.67 | +0.54% | $1.41B | — | — | 1.4 | +5.8% |
| Beta Bionics | $19.55 | +0.67% | $873.5M | — | — | 7.3 | +37.8% |
| Vertex Pharmaceuticals | $556.75 | +0.01% | $141.31B | 32.4 | 28.6 | 11.2 | +12.5% |
| Median | 30.0 | 28.6 | 3.4 | +18.0% |